vs

Side-by-side financial comparison of Castellum, Inc. (CTM) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Castellum, Inc. is the larger business by last-quarter revenue ($12.6M vs $12.5M, roughly 1.0× Avidity Biosciences, Inc.). Castellum, Inc. runs the higher net margin — -10.5% vs -1398.3%, a 1387.8% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 21.9%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 5.3%).

Castellum, Inc. is a U.S.-based cybersecurity and information technology services provider. It caters to government defense agencies, public sector entities, and commercial enterprise clients, offering threat detection, data protection, cloud security, and managed IT solutions to help organizations mitigate cyber risks and safeguard critical digital infrastructure.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

CTM vs RNA — Head-to-Head

Bigger by revenue
CTM
CTM
1.0× larger
CTM
$12.6M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+412.1% gap
RNA
434.0%
21.9%
CTM
Higher net margin
CTM
CTM
1387.8% more per $
CTM
-10.5%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
5.3%
CTM

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CTM
CTM
RNA
RNA
Revenue
$12.6M
$12.5M
Net Profit
$-1.3M
$-174.4M
Gross Margin
33.9%
Operating Margin
-11.1%
-1513.5%
Net Margin
-10.5%
-1398.3%
Revenue YoY
21.9%
434.0%
Net Profit YoY
51.8%
-117.0%
EPS (diluted)
$-0.02
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTM
CTM
RNA
RNA
Q4 25
$12.6M
Q3 25
$14.6M
$12.5M
Q2 25
$14.0M
$3.8M
Q1 25
$11.7M
$1.6M
Q4 24
$10.3M
$3.0M
Q3 24
$11.6M
$2.3M
Q2 24
$11.5M
$2.0M
Q1 24
$11.3M
$3.5M
Net Profit
CTM
CTM
RNA
RNA
Q4 25
$-1.3M
Q3 25
$415.4K
$-174.4M
Q2 25
$-322.1K
$-157.3M
Q1 25
$-1.2M
$-115.8M
Q4 24
$-2.7M
$-102.3M
Q3 24
$-1.3M
$-80.4M
Q2 24
$-1.8M
$-70.8M
Q1 24
$-4.1M
$-68.9M
Gross Margin
CTM
CTM
RNA
RNA
Q4 25
33.9%
Q3 25
37.6%
Q2 25
36.1%
Q1 25
39.0%
Q4 24
40.0%
Q3 24
42.7%
Q2 24
40.6%
Q1 24
39.8%
Operating Margin
CTM
CTM
RNA
RNA
Q4 25
-11.1%
Q3 25
3.0%
-1513.5%
Q2 25
-2.7%
-4448.7%
Q1 25
-12.7%
-8360.9%
Q4 24
-15.7%
-4069.6%
Q3 24
-11.9%
-4200.9%
Q2 24
-13.6%
-4040.4%
Q1 24
-23.6%
-2178.6%
Net Margin
CTM
CTM
RNA
RNA
Q4 25
-10.5%
Q3 25
2.8%
-1398.3%
Q2 25
-2.3%
-4089.3%
Q1 25
-10.0%
-7360.0%
Q4 24
-26.6%
-3439.5%
Q3 24
-11.0%
-3441.7%
Q2 24
-16.0%
-3461.8%
Q1 24
-36.3%
-1943.4%
EPS (diluted)
CTM
CTM
RNA
RNA
Q4 25
$-0.02
Q3 25
$0.00
$-1.27
Q2 25
$0.00
$-1.21
Q1 25
$-0.01
$-0.90
Q4 24
$-0.05
$-0.80
Q3 24
$-0.02
$-0.65
Q2 24
$-0.03
$-0.65
Q1 24
$-0.08
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTM
CTM
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$35.8M
$1.9B
Total Assets
$41.9M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTM
CTM
RNA
RNA
Q4 25
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Total Debt
CTM
CTM
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.0M
Q3 24
$8.3M
Q2 24
$8.7M
Q1 24
$9.0M
Stockholders' Equity
CTM
CTM
RNA
RNA
Q4 25
$35.8M
Q3 25
$36.7M
$1.9B
Q2 25
$31.8M
$1.2B
Q1 25
$26.1M
$1.3B
Q4 24
$20.2M
$1.4B
Q3 24
$12.0M
$1.5B
Q2 24
$12.1M
$1.2B
Q1 24
$12.8M
$830.9M
Total Assets
CTM
CTM
RNA
RNA
Q4 25
$41.9M
Q3 25
$46.3M
$2.1B
Q2 25
$43.4M
$1.4B
Q1 25
$41.1M
$1.5B
Q4 24
$37.8M
$1.6B
Q3 24
$28.8M
$1.6B
Q2 24
$29.5M
$1.3B
Q1 24
$30.5M
$951.5M
Debt / Equity
CTM
CTM
RNA
RNA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.40×
Q3 24
0.69×
Q2 24
0.72×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTM
CTM
RNA
RNA
Operating Cash FlowLast quarter
$-661.7K
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTM
CTM
RNA
RNA
Q4 25
$-661.7K
Q3 25
$1.0M
$-156.2M
Q2 25
$214.2K
$-199.7M
Q1 25
$-2.5M
$-124.8M
Q4 24
$-394.4K
$-99.9M
Q3 24
$742.2K
$-65.6M
Q2 24
$748.6K
$-65.0M
Q1 24
$23.7K
$-70.4M
Free Cash Flow
CTM
CTM
RNA
RNA
Q4 25
Q3 25
$957.0K
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$738.9K
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
CTM
CTM
RNA
RNA
Q4 25
Q3 25
6.5%
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
6.4%
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
CTM
CTM
RNA
RNA
Q4 25
Q3 25
0.3%
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
0.0%
131.7%
Q3 24
0.0%
72.9%
Q2 24
0.0%
26.0%
Q1 24
0.0%
25.8%
Cash Conversion
CTM
CTM
RNA
RNA
Q4 25
Q3 25
2.41×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons